Gamida for Life Buys Elitech's Microarray Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Gamida For Life Group has acquired electronic microarray technologies from the Elitech Group, a private group of in vitro diagnostics and reagent companies, for an undisclosed sum, Elitech said today.

Paris-based Elitech said that the intellectual property and tangible assets Gamida bought was from Epoch Bioscience, part of Elitech's Wescor division, and were originally acquired from Nanogen in July, 2009, for $25.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.